Comorbidities Impacting COVID-19 Outcomes

The course and severity of COVID-19 infection are profoundly influenced by the presence of pre-existing health conditions. Chronic diseases of the cardiovascular, respiratory and renal systems emerge consistently as the strongest predictors of hospitalisation, critical care admission and mortality. Metabolic disorders such as diabetes and obesity further amplify risk, reflecting underlying chronic inflammation and immune dysregulation. Neurological conditions, notably dementia and other neurodegenerative disorders, increase vulnerability through diminished physiological reserve and barriers to prompt symptom recognition. Cancer and immunosuppressive states compromise host defences, while hypertension and cerebrovascular disease contribute via endothelial dysfunction and heightened thrombotic potential. The impact of comorbidities has shifted as viral variants, vaccination coverage and treatment protocols evolved, yielding differences in relative risk across pandemic waves. Ethnic and socioeconomic disparities intersect with comorbidity profiles to produce variable outcomes around the globe. Understanding these interactions underpins targeted prevention strategies, informed clinical triage and resource allocation, and guides tailored public health policy designed to protect the most vulnerable.

Research from Nature Portfolio

A large systematic review and meta-analysis examined geographic variation in the prevalence of key comorbidities and their association with COVID-19 severity and mortality. Across more than one hundred studies, hypertension, obesity, diabetes and cardiovascular disease were the most common underlying conditions. However, risk of severe disease and death varied markedly by region: mortality was highest in European and Latin American cohorts, while severity among individual comorbid states peaked in some Asian studies. The analysis highlighted chronic kidney disease, cerebrovascular accident and cardiovascular disease as predictors of both worse disease progression and fatality. These findings underscore the need to adapt intervention strategies—such as vaccine prioritisation and clinical protocols—to regional comorbidity burdens and demographic characteristics.

Comorbidities Impacting COVID-19 Outcomes publication trend

The graph below shows the total number of articles in comorbidities impacting covid-19 outcomes across all publications each year (not limited to Nature Index journals).

Technical terms

Comorbidity: The coexistence of one or more additional medical conditions alongside a primary disease, influencing its course and management.

Odds Ratio (OR): A measure of association indicating the odds of an outcome occurring in one group relative to another.

Hazard Ratio (HR): A metric from time-to-event analysis expressing how often a particular event happens in one group compared with another over time.

Retrospective Cohort Study: An observational design that examines outcomes in a group of individuals by analysing pre-existing records from a defined past period.

Meta-Analysis: A statistical approach that combines results from multiple independent studies to produce pooled estimates of effect.

Intensive Care Unit (ICU): A specialised hospital department providing advanced life support and monitoring for critically ill patients.

References

1. SARS-CoV-2 susceptibility and COVID-19 illness course and outcome in people with pre-existing neurodegenerative disorders: systematic review with frequentist and Bayesian meta-analyses. The British Journal of Psychiatry (2023).
2. Relevance of comorbidities for main outcomes during different periods of the COVID‐19 pandemic. Influenza and Other Respiratory Viruses (2024).
3. Comorbidities associated with the severity of COVID-19, and differences across ethnic groups: a UK Biobank cohort study. BMC Public Health (2023).
4. A systematic review and meta-analysis of geographic differences in comorbidities and associated severity and mortality among individuals with COVID-19. Scientific Reports (2021).